Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Eldepryl

Eldepryl
In stock
5mg · 10mg
from 25,22 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
33,02 £27,52 £
0,92 £ per tablet

In brief

  • In the UK, Eldepryl is a prescription-only medicine (POM) normally dispensed from pharmacies with a valid prescription.
  • Eldepryl (selegiline) is used primarily as an adjunct treatment for Parkinson’s disease; it is a selective monoamine oxidase B (MAO‑B) inhibitor that reduces the breakdown of dopamine in the brain, thereby enhancing dopaminergic activity.
  • Usual adult doses for Parkinson’s disease are 5–10 mg daily (commonly 5 mg twice daily) for tablets; orally disintegrating tablets are typically 1.25–2.5 mg once daily. Doses may be adjusted when used with levodopa/carbidopa.
  • Forms of administration include oral tablets (5 mg, 10 mg) and orally disintegrating tablets (1.25 mg Zelapar).
  • Onset of symptomatic benefit is variable: some patients notice improvements within a few days, but meaningful clinical effects often take several weeks of continuous treatment.
  • Duration of action is maintained with daily dosing; MAO‑B inhibition and symptomatic coverage are typically managed with once- or twice‑daily administration, with clinical benefits persisting while treatment continues.
  • Avoid excessive alcohol; alcohol can worsen side effects such as dizziness and drowsiness and may increase the risk of adverse cardiovascular or central nervous system effects when combined with selegiline or with tyramine-rich foods.
  • The most common side effect is nausea; other frequent effects include dry mouth, dizziness, insomnia, headache, abdominal pain, increased sweating and orthostatic hypotension.
  • Would you like to try Eldepryl without a prescription?

Basic Eldepryl information

  • INN (international nonproprietary name): Selegiline.
  • Brand names available in the United Kingdom: Eldepryl — tablets 5 mg and 10 mg in blister packs of 28 or 100.
  • ATC code: N04BD01 (monoamine oxidase B inhibitors, anti‑Parkinson drugs).
  • Forms and dosages: Tablets 5 mg and 10 mg (blisters 28, 100); orally disintegrating tablet (Zelapar) 1.25 mg.
  • Manufacturers in the United Kingdom: Sovereign Medical.
  • Registration status in the United Kingdom: Prescription-only medicine, licensed by the MHRA.
  • OTC / Rx classification: Prescription-only medicine (POM).

Critical warnings and restrictions

High‑risk groups (elderly, pregnancy, chronic illness)

Who should worry first is a common question from patients and clinicians.

Absolute contraindications include known hypersensitivity to selegiline or excipients, concomitant use with other monoamine oxidase inhibitors, opioid analgesics such as pethidine, and certain strong serotonergic agents because of the risk of serotonin syndrome.

Phaeochromocytoma is an absolute contraindication due to the risk of hypertensive crisis.

Pregnancy and breastfeeding require careful specialist review because selegiline is a prescription‑only medicine and the risk/benefit must be discussed with neurology and obstetrics teams before starting therapy.

In older patients start at the lower end of the dosing range and titrate carefully.

Elderly people are at higher risk of orthostatic hypotension, hallucinations and drug interactions caused by polypharmacy; monitoring is essential.

Patients with liver or kidney impairment need dose adjustment and clinical monitoring because clearance may be reduced.

  • Contraindicated drugs: Other MAOIs; pethidine; potent serotonergic antidepressants and combinations that raise serotonin significantly.
  • Tyramine‑rich foods: Aged cheeses, cured meats (salami, prosciutto), fermented products (soy sauce, kimchi), certain matured yeast extracts, and improperly stored broad‑range fermented foods.

Pre‑prescription safety checklist for clinicians:

  • Complete medication history including OTC and herbal products.
  • Baseline blood pressure and orthostatic measurements.
  • Psychiatric history noting psychosis, mania or severe depression.
  • Assess liver and renal function and recent LFTs/renal profile.
  • Confirm pregnancy status and breastfeeding plans; perform pregnancy test if applicable.
  • Document rationale for selegiline and plan for follow‑up monitoring.

Interaction with activities (driving, workplace safety under UK law)

Dizziness, insomnia and hallucinations are possible and may impair driving or the safe operation of machinery.

Patients must be advised not to drive if they experience these effects and to report them promptly to their clinician.

Pharmacy counselling should include discussion of workplace safety and fitness to drive at dispensing.

DVLA reporting criteria
Patients must inform the DVLA if a condition or medication affects their ability to drive.
Employer responsibility
Employers should assess fitness for work where tasks involve safety‑critical duties.

Q&A — Can I drive after taking it in the UK?

Q: Can I drive after taking selegiline (Eldepryl)?

A: If you experience dizziness, excessive drowsiness, hallucinations or impaired concentration, do not drive or operate machinery.

A: Inform your clinician and check DVLA guidance because your fitness to drive must be reassessed if medication or Parkinson’s symptoms affect driving.

A: Report adverse effects via the MHRA Yellow Card scheme.

Usage basics

INN, brand names available in the UK

Patients often ask for the generic name they can recognise on a prescription.

INN: Selegiline is the International Nonproprietary Name.

UK brand: Eldepryl is marketed as tablets in 5 mg and 10 mg strengths sold in blister packs of 28 or 100.

Selegiline is also available as Zelapar orally disintegrating tablets (ODT).

Brand Form Strength
Eldepryl Tablet 5 mg, 10 mg
Zelapar Orally disintegrating tablet 1.25 mg

Legal classification (POM, P, GSL)

Selegiline is a prescription-only medicine (POM) throughout the UK.

It must be prescribed by an authorised prescriber and dispensed by community or online pharmacies with an appropriate prescription.

  • Authorised prescribers: GPs, hospital consultants, specialist neurologists.
  • Dispensing pathways: NHS electronic prescription service (e‑prescription), standard private prescriptions, community pharmacy supply.

Dosing guide

Standard regimens (NHS guidelines)

Patients and clinicians want a clear sense of typical dosing to set expectations.

For Parkinson’s disease standard adult dosing is 5–10 mg daily, commonly 5 mg twice daily for oral tablets.

ODT dosing (Zelapar) is lower, typically 1.25–2.5 mg once daily.

Selegiline is often used adjunctively with levodopa/carbidopa and doses may be adjusted when combined to reduce wearing‑off.

An elderly patient example: start at 5 mg once daily and assess for hypotension, hallucinations and sleep disturbance before increasing.

Use Starting dose Usual maintenance Maximum ODT equivalent
Parkinson’s disease 5 mg once daily (elderly start lower) 5 mg twice daily (total 10 mg) 10 mg daily 1.25–2.5 mg once daily (Zelapar)

Adjustments for comorbidities

Liver or kidney impairment can reduce clearance so use lower doses and monitor clinically.

Paediatric use is not established and generally not recommended.

Polypharmacy is common in Parkinson’s patients; review for interactions with antidepressants, tramadol, dextromethorphan, triptans and methadone among others.

Q&A — What if I miss a dose?

Q: Missed dose instruction?

A: Take the missed dose as soon as you remember unless the next dose is imminent.

A: Do not double up on doses to make up for a missed one.

A: If in doubt contact your GP or pharmacist for personalised advice.

A: For orally disintegrating tablets do not take extra tablets without professional advice.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

Patients commonly worry about what happens if they eat cheese or drink alcohol while on selegiline.

Tyramine‑containing foods can cause hypertensive events with non‑selective MAOIs.

At standard selegiline doses selective MAO‑B inhibition limits tyramine risk, but caution remains at higher doses.

Alcohol may worsen orthostatic hypotension and should be used in moderation while monitoring symptoms.

  • Foods to avoid: Aged cheeses, cured meats, fermented soy products, certain preserved or improperly stored foods that are high in tyramine.
  • Foods generally safe: Fresh fruits, vegetables, fresh meats and dairy products without ageing or fermentation.

Common drug conflicts

Certain interactions carry significant risk including serotonin syndrome or hypertensive crisis.

Report suspected interactions or adverse reactions to the MHRA Yellow Card scheme to aid surveillance.

Interaction Severity Action
Other MAOIs Contraindicated Do not co‑prescribe
Pethidine Contraindicated Avoid; alternative analgesic needed
SSRIs, SNRIs, TCAs, triptans High risk Avoid or allow adequate washout per SPC
Sympathomimetics Caution Monitor BP and consider alternatives

Legal status and availability in the UK

In our online pharmacy, Eldepryl is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Selegiline is an MAO‑B inhibitor and works by selectively blocking monoamine oxidase B to slow dopamine breakdown in the brain.

Increased central dopaminergic activity improves motor symptoms in Parkinson’s disease.

MAO‑B vs MAO‑A
MAO‑B mainly metabolises dopamine; MAO‑A metabolises serotonin and noradrenaline.
Dopaminergic neurotransmission
Blocking MAO‑B increases synaptic dopamine availability and reduces motor symptoms.
ODT definition
Orally disintegrating tablet that dissolves on the tongue for rapid absorption.

Clinical terms

Onset of symptomatic effect may be seen in days to weeks while long‑term levodopa‑sparing benefits are assessed over months.

At higher doses selegiline may lose MAO‑B selectivity and increase the risk of interactions seen with non‑selective MAOIs.

  • Mechanism steps: Inhibit MAO‑B → reduce dopamine breakdown → increase dopamine in striatum → improved motor function.
  • Clinical implications: Monitor for orthostatic hypotension, sleep disturbance and psychiatric effects; adjust when combined with levodopa.

Refer to product SPCs and MHRA guidance for precise pharmacokinetic figures and formulation differences.

Indications and off‑label uses

MHRA‑approved uses

The UK indication is Parkinson’s disease, either alone in early disease or as an adjunct to levodopa, to increase central dopaminergic activity and manage motor symptoms.

Selegiline has regulatory approval and is a prescription medicine for this indication.

Off‑label practices in NHS and private care

Eldepryl oral tablets are indicated for Parkinson’s disease.

Off‑label use requires documented clinical rationale, informed consent and local governance approval when used in NHS or private practice.

  • Approved indications: Adjunctive treatment of Parkinson’s disease alongside levodopa/carbidopa.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Drug Mechanism Dosing frequency Common AEs Monitoring
Selegiline (Eldepryl) MAO‑B inhibitor Twice daily (oral) Nausea, insomnia, dizziness, orthostatic hypotension BP, LFTs if indicated, medication review
Rasagiline MAO‑B inhibitor Once daily Headache, nausea, insomnia Medication review, BP
Safinamide Reversible MAO‑B inhibitor Once daily Peripheral oedema, dyskinesia LFTs, clinical review
Entacapone COMT inhibitor With each levodopa dose Diarrhoea, urine discoloration Medication review, hepatic monitoring for tolcapone

Pros and cons checklist

  • Severity of symptoms: Consider MAO‑B if early motor fluctuations present.
  • Dyskinesia profile: COMT inhibitors or dose modification may be preferred if dyskinesia problematic.
  • Drug interactions: Review serotonergic agents and opioids before MAO‑B initiation.
  • Renal/hepatic status: Factor in dose adjustments and monitoring needs.
  • Patient preference: Once‑daily dosing (rasagiline, safinamide) may aid adherence.

Local NHS formularies should guide final prescribing decisions.

Common questions

  • Will selegiline interact with my antidepressant?
    Many antidepressants including SSRIs, SNRIs, TCAs and other MAOIs can precipitate serotonin syndrome and should not be used concomitantly; allow appropriate washout periods as stated in the SPC.
  • Can I eat cheese?
    At standard selegiline doses MAO‑B selectivity generally limits tyramine risk, but caution is advised with higher doses; discuss dietary guidance with your pharmacist.
  • How quickly will it work?
    Some symptomatic benefit can appear within days to weeks; levodopa‑sparing effects and sustained benefit are assessed over months.

Always reference MHRA and NHS guidance for safety checks and monitoring schedules.

Registration and regulation

MHRA approval process

Selegiline (Eldepryl) is an approved prescription medicine and clinicians should consult the MHRA and the product SPC for up‑to‑date safety communications and licensing details.

NHS prescribing framework

The NHS e‑prescription service supports electronic transmission of prescriptions to pharmacies and repeat prescribing is managed in primary care under local protocols.

  • Steps for reporting ADRs: Submit suspected adverse reactions via the MHRA Yellow Card scheme online or through the Yellow Card app.
  • Where to find SPC and BNF entries: MHRA website, electronic Medicines Compendium (eMC) and the British National Formulary.

Storage and handling

UK household storage (cold/damp climate)

Store medicine in the original packaging at room temperature below 25°C and keep it away from moisture and direct light.

Do not refrigerate or freeze tablets or capsules and keep all medicines out of reach of children.

Patient home storage checklist:

  • Keep in a dry cupboard away from bathrooms and sinks.
  • Keep blister packs intact until use.
  • Return unused medicines to the pharmacy for safe disposal.

Guidance from NHS and pharmacists

Pharmacists should advise patients to transport medicines in original packaging and to carry required medicines in hand luggage when travelling by air.

Community pharmacies should check blister integrity on receipt and provide the patient information leaflet at dispensing.

Travel/holiday storage tips:

  • Carry medicines in hand luggage to control temperature and avoid loss.
  • Keep a copy of the prescription or NHS summary in case of queries abroad.

Guidelines for proper use

UK pharmacist counselling style

At dispensing confirm the indication, review the patient’s full medication list and highlight specific interaction risks with serotonergic agents and opioids.

Ask about pregnancy and breastfeeding and counsel on common side effects such as nausea, insomnia and dizziness.

Explain missed dose policy, storage advice and the need to report adverse effects to the Yellow Card scheme.

Counselling script checklist:

  • Confirm diagnosis and intended duration of treatment.
  • Review interactions with antidepressants, tramadol, dextromethorphan, triptans and methadone.
  • Advise on driving safety and DVLA reporting where applicable.
  • Arrange or advise on follow‑up review with GP or neurology clinic.

NHS patient safety advice

Document shared decision‑making and provide the patient information leaflet at supply.

Signpost to NHS patient resources and encourage Yellow Card reporting for suspected adverse reactions.

Recommended follow‑up schedule and monitoring checklist:

  • Review within 4–12 weeks after initiation to assess motor response and adverse effects.
  • Monitor blood pressure (including orthostatic readings), medication review and LFTs if clinically indicated.
  • Ongoing medication reconciliation for polypharmacy risks.

Refer to product SPCs for complete contraindication and dosing details.

Delivery across the United Kingdom

City Region Delivery time
London England 5‑7 days
Birmingham England 5‑7 days
Manchester England 5‑7 days
Glasgow Scotland 5‑7 days
Edinburgh Scotland 5‑7 days
Leeds England 5‑7 days
Bristol England 5‑7 days
Liverpool England 5‑7 days
Newcastle Upon Tyne England 5‑9 days
Sheffield England 5‑9 days
Nottingham England 5‑9 days
Leicester England 5‑9 days
Coventry England 5‑9 days
Plymouth England 5‑9 days

Final notes for clinicians and patients

Selegiline (Eldepryl) remains a recognised MAO‑B inhibitor used adjunctively in Parkinson’s disease to improve motor symptoms and potentially delay levodopa dose escalation.

Ensure contraindications such as concomitant MAOIs, pethidine and phaeochromocytoma are excluded before prescribing.

Start at the lower end of the dosing range in elderly patients, monitor for orthostatic hypotension and hallucinations, and review all concomitant medications to reduce interaction risk.

Related products